CheckMate914

Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis - Mori - International Journal of Urology - Wiley Online Library

Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC

Checkpoint inhibitor immunotherapy in kidney cancer

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - ScienceDirect

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments

ESMO22: CheckMate 914-studie naar adjuvant nivo+ipi bij RCC behaalt primaire uitkomstmaat niet - Oncologie

日本がん対策図鑑 【腎細胞がん：術後治療（DFS）】「オプジーボ＋ヤーボイ」vs「経過観察」

Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro

A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)

Enrique Grande on X: 🔘 On @TheLancet - Assessing the efficacy and safety of adjuvant nivolumab + ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914) #immunotherapy #kidneycancer

EIKCS 2022: Selecting Renal Cell Carcinoma Patients for Adjuvant Therapy